BioCentury | Jan 3, 2019
Distillery Therapeutics

Renal

INDICATION: Renal damage Mouse studies suggest inhibiting AKR1A1 or PKM2 could help treat acute kidney injury (AKI). In a mouse model of AKI, systemic AKR1A1 knockout or renal-specific PKM2 knockout increased survival and decreased tubular...
BioCentury | Sep 29, 2017
Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
BioCentury | Nov 30, 2016
Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies suggest inhibiting PKM2 could help treat sepsis. In lipopolysaccharide (LPS)-pretreated mouse bone marrow-derived macrophages and a human monocytic cell line, PKM2 knockdown or a PKM2 inhibitor tool compound...
BioCentury | Dec 10, 2015
Distillery Techniques

Techniques: Pyruvate kinase M2 isozyme (PKM2)-targeting PET imaging agent for tumor detection

Imaging TECHNOLOGY: PET A PKM2-targeting PET imaging agent could help detect tumors. The agent consisted of an N,N-diarylsulfonamide that binds PKM2 - an enzyme expressed in all cancers and required for tumor glycolysis - linked to the...
BioCentury | Jun 16, 2014
Company News

Agios, Celgene deal

Celgene exercised its option under a 2010 cancer metabolism deal with Agios to license exclusive, worldwide rights to develop and commercialize Agios' AG-221 , an inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) . The compound is in...
BioCentury | Feb 10, 2014
Company News

Agios, Celgene deal

Agios exercised its option under a 2010 cancer metabolism deal with Celgene to retain U.S. development and commercialization rights to the isocitrate dehydrogenase 1 (IDH1) program, including AG-120 . AG-120, an inhibitor of mutated IDH1, is...
BioCentury | Dec 16, 2013
Company News

Agios, Celgene deal

Agios and Celgene extended by a year to April 2015 a 2010 cancer metabolism deal, triggering a $20 million payment to Agios. Celgene will now have five years of exclusivity, up from four years, during...
BioCentury | Jan 24, 2013
Distillery Therapeutics

Indication: Cancer

...Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Pyruvate kinase M2 isozyme (PKM2); PKM1...
...colon carcinoma or adenocarcinoma cells, small hairpin RNA-mediated knockdown of PKM1 and PKM2, but not PKM1...
...in mouse xenograft models of established colon carcinoma or adenocarcinoma, individual or dual inhibition of PKM1...
BioCentury | Jan 17, 2013
Targets & Mechanisms

What to do with PKM2

...is too early to write off the target. Pyruvate kinase occurs as two main isoforms- pyruvate kinase M1 isozyme (PKM1)...
...or a low-activity dimer. PKM2's oligomerization and activity is allosterically regulated by glycolysis intermediates. The PKM1...
...established tumors. In cultured colon carcinoma or adenocarcinoma cells, small hairpin RNA-mediated knockdown of both PKM1...
BioCentury | Jan 14, 2013
Company News

ExperGen, Thallion cancer news

Thallion said it received a final binding award from the International Chamber of Commerce International Court of Arbitration rejecting all claims for damages by ExperGen in a dispute over a 2006 deal under which Thallion...
Items per page:
1 - 10 of 46